RxDoctor Payments Data

David Hayes

Cardiovascular Disease · Austin, TXNPI 1093801581

Payments from drug & device makers

$545in general payments, 2019–2025

Across 30 payments — averaging $18.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$203
  • Novartis$39
  • Boston Scientific$37
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$31
  • Alk-abello, Inc$31
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$27
  • plus $177 from 10 others

What the payments were for

  • Food & beverage$545100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$545 in reported general payments places this provider in the 15th percentile of 1,515 cardiovascular disease providers in Texas.

See all cardiovascular disease providers in Texas

Medicare billing

Part B allowed, 2024
$141,319
Medicare patients
491
Services billed
1,358

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban212$202,487
XareltoRivaroxaban129$162,559
EntrestoSacubitril/Valsartan18$16,798
Repatha SureclickEvolocumab22$15,759
BrilintaTicagrelor12$7,357
LivaloPitavastatin Calcium12$6,877
Metoprolol Succinate445$6,695
Losartan Potassium386$4,662
Atorvastatin Calcium354$4,130
Rosuvastatin Calcium361$3,980
Flecainide Acetate107$3,603
Lisinopril276$3,503
Amlodipine Besylate349$3,377
Carvedilol304$3,110
ClopidogrelClopidogrel Bisulfate203$3,038

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$26$202,487212 claims
Johnson & JohnsonXarelto$14$162,559129 claims
NovartisEntresto$39$16,79818 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 15th percentile of 1,515 cardiovascular disease providers in Texas.

Other cardiovascular disease in Austin

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →